MEDICINAL PRODUCT FOR THE THERAPEUTIC TREATMENT AND/OR IMPROVEMENT OF THE CONDITION OF SEPSIS ASSOCIATED WITH COAGULOPATHY Russian patent published in 2023 - IPC A61K38/36 A61P7/02 

Abstract RU 2799764 C2

FIELD: medicine.

SUBSTANCE: invention relates to a method of therapeutic treatment and/or improvement of the condition of a patient with sepsis. A method of therapeutic treatment and/or improvement of the condition of a patient with sepsis involves administering a medicinal product containing thrombomodulin as an active ingredient, where the said medicinal product is administered to a patient whose International Normalized Ratio (INR) value is greater than 1.4 immediately prior to administration, where the term “immediately before administration” means a period of 1 hour, calculated retrospectively from the start of administration of a medicinal product containing thrombomodulin, where the medicinal product is administered to a patient whose platelet count is greater than 30,000/mm3 just before administration.

EFFECT: above invention provides a method of effective therapeutic treatment and/or improvement in sepsis accompanied by coagulopathy.

11 cl, 1 dwg, 4 tbl, 8 ex

Similar patents RU2799764C2

Title Year Author Number
THERAPY MONITORING IN TREATMENT WITH BINDING AGENT AGAINST ADRENOMEDULLIN (ADM) 2018
  • Struck, Joachim
  • Bergmann, Andreas
RU2776811C2
ANTI-ORAI1 ANTIBODY 2015
  • Komai Tomoaki
  • Kimura Takako
  • Baba Daichi
  • Onodera Yoshikuni
  • Tanaka Kento
  • Kagari Takashi
  • Aki Anri
  • Nagaoka Nobumi
RU2724742C2
GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS 2014
  • Dr. Wagner Thomas
  • Carlsson Malin
  • Staum Kaltoft Margit
RU2714919C2
PREDICTION OF RISK OF DEVELOPMENT OF UNDESIRED REACTION RELATED TO ADMINISTRATION OF ANTIBODY TO ALK2 AND CAPABILITY OF RESPONDING TO TREATMENT WITH ANTIBODY TO ALK2 2019
  • Katagiri Takenobu
  • Tsukamoto Sho
  • Kumagai Keigo
  • Tsuji Shinnosuke
RU2783762C2
CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY 2015
  • Galetto Roman
RU2727290C2
MONOCLONAL ANTIBODY TO ACTIVATED PROTEIN FROM HUMAN AND PRODUCTION AND USE THEREOF 2021
  • Xu Jun
  • Cheng Lu
  • Yi Jiawei
  • Xia Zhisong
  • Liu Yeheng
RU2824515C1
ANTITUMOR AGENT AND A METHOD OF ITS EVALUATION 2019
  • Tanaka Yuki
RU2803148C2
NEW FAB-FRAGMENT OF HUMAN NGF ANTIBODY 2016
  • Tanaka, Hirotsugu
  • Fujita, Hirotada
  • Aoki, Toshiaki
RU2729825C2
FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE 2020
  • Dun, Chzhao
  • Chzhou, Chi
  • Chzhan, Tsziyu
  • Li, Yuanli
  • Li, Tsyan
RU2804335C2
VERSIONS AND ISOFORMS OF ANTIBODIES WITH REDUCED BIOLOGICAL ACTIVITY 2018
  • Khosoguti Kensaku
  • Kuvayama Maki
  • Sejda Tifumi
  • Vatanabe Esuke
  • Tanaka Nobuyuki
  • Sajto Satosi
  • Fukuda Masakadzu
RU2813990C2

RU 2 799 764 C2

Authors

Matsuki, Osamu

Tanaka, Kosuke

Tanaka, Risa

Dates

2023-07-11Published

2019-08-01Filed